Pan-cancer therapies, such as larotrectinib and entrectinib for NTRK rearrangement tumors (17, 18), and dabrafenib combined with trametinib for treating BRAF V600E-mutated patients (19, 20), could also have promising efficacy against BTC. This evidence concerns the gene BRAF and cancer.